drugset / Trial / NCT05916326
Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha)
Phase 3
Completed
8000 enrolled
National Vaccine and Serum Institute, China
Lanzhou Institute of Biological Products Co., Ltd · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to evaluate the Efficacy, Safety and Immunogenicity of the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) in Healthy People Aged 6 Months to 13 Years After Vaccination
Timeline
- Start
- 2023-06-30
- Primary completion
- 2025-07-27
- Completion
- 2025-07-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) | Vaccine | — | Intramuscular |